Orthopedics: Bracing For Change

Despite ongoing economic pressures, the worldwide orthopedic market grew 3% in 2014, reaching $34.7 billion. Although consolidation continues to cause uncertainty and disruption in this space, manufacturers at this year’s AAOS meeting were upbeat about the future as they brace for changes in the competitive landscape, health care delivery, and reimbursement.

The mood was upbeat – yet tentative – at this year’s Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS 2015) held in Las Vegas in March as the industry braces for transformational change. Upbeat because the orthopedic market has returned to historical growth rates with stable procedural volumes across all segments in spite of significant pricing pressure; tentative owing to the inevitable disruption that will result from mega deals taking place in this space. Two large transactions will soon close that are of such scale, it will no doubt alter the orthopedic landscape while creating uncertainty among stakeholders at all levels: Zimmer Biomet Holdings Inc.’s $13.35 billion merger with the number four player, Biomet Inc., will create a formidable number two player in the global orthopedic market with $7.8 billion in combined revenues that will surpass Stryker Corp.; and Wright Medical Group NV’s $3.3 billion merger with Tornier NV in an all-stock transaction will create a pure-play extremities/biologics company with a combined ownership by 52% of Wright’s and 48% of Tornier’s shareholders. (See [A#2014700061].) [See Deal][See Deal]

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Roche’s $50Bn Bet On US Manufacturing: Tariff Shield But Cash Flow Strain

 
• By 

New continuous glucose monitoring manufacturing site in Indiana is part of Roche’s plan to boost its US presence. Roche’s launch of Accu-Chek SmartGuide system last year with AI-powered prediction capabilities puts it as a key differentiator from competitors such as Abbott and Dexcom.

Analysts See Insulet’s Appointment Of Ashley McEvoy As CEO As A Positive Move

 
• By 

Diabetes company Insulet announced that former longtime J&J executive Ashley McEvoy will succeed Jim Hollingshead as president and CEO effective today. Analysts applauded the appointment, noting McEvoy’s strong background in medtech and diabetes.

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

 

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.

OneCell Diagnostics – Now 1Cell.Ai - Launches Multi-Modal Cancer Diagnostic Panel OncoIncytes

 

OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.

More from Business

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.

Roche Diagnostics Hit By China Reforms As Q1 Sales Remain Flat

 
• By 

While Roche continues to view China as a strategic growth market, a sharp 23% decline in Chinese diagnostics sales offset gains in other regions and segments. Despite near-term headwinds, Roche is betting on strong instrument placement growth across its Core Lab, Molecular, and Near Patient Care segments to fuel future demand for consumables and services–key components of its long-term medtech strategy.

Roche’s $50Bn Bet On US Manufacturing: Tariff Shield But Cash Flow Strain

 
• By 

New continuous glucose monitoring manufacturing site in Indiana is part of Roche’s plan to boost its US presence. Roche’s launch of Accu-Chek SmartGuide system last year with AI-powered prediction capabilities puts it as a key differentiator from competitors such as Abbott and Dexcom.